Clinical Trial Update: AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AFP464 in patients with metastatic or unresectable solid tumors completed; the trial enrolled patients with various cancers including b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• AFP464

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: COMPLETED